Diagnosis and treatment of chronic acquired demyelinating polyneuropathies, Nature Reviews Neurology, vol.60, issue.8, pp.435-446, 2014. ,
DOI : 10.1517/13543784.2012.685650
Distal acquired demyelinating symmetric neuropathy, Neurology, vol.54, issue.3, pp.615-620, 2000. ,
DOI : 10.1212/WNL.54.3.615
Plasma-Cell Dyscrasia and Peripheral Neuropathy with a Monoclonal Antibody to Peripheral-Nerve Myelin, New England Journal of Medicine, vol.303, issue.11, pp.618-621, 1980. ,
DOI : 10.1056/NEJM198009113031105
CHRONIC DEMYELINATING NEUROPATHY ASSOCIATED WITH BENIGN IGM PARAPROTEINAEMIA, Brain, vol.106, issue.1, pp.169-195, 1983. ,
DOI : 10.1093/brain/106.1.169
Prevalence of Monoclonal Gammopathy of Undetermined Significance, New England Journal of Medicine, vol.354, issue.13, pp.1362-1369, 2006. ,
DOI : 10.1056/NEJMoa054494
Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management, Am J Hematol. 2013, vol.88, issue.8, pp.703-711 ,
Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project, Blood, vol.116, issue.19, pp.3724-3734, 2010. ,
DOI : 10.1182/blood-2010-05-282632
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network, Haematologica, vol.99, issue.6, pp.984-996, 2014. ,
DOI : 10.3324/haematol.2013.100552
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management, Leukemia, vol.102, issue.6, pp.1121-1127, 2010. ,
DOI : 10.1182/blood-2007-08-108357
Peripheral neuropathies in Waldenstrom's macroglobulinaemia, Journal of Neurology, Neurosurgery & Psychiatry, vol.77, issue.2, pp.224-228, 2006. ,
DOI : 10.1136/jnnp.2005.071175
Monoclonal gammopathy and neuropathy, Current Opinion in Neurology, vol.22, issue.5, 2009. ,
DOI : 10.1097/WCO.0b013e32832fd563
Anti-myelin-associated glycoprotein neuropathy, Current Opinion in Neurology, vol.19, issue.5, pp.458-463, 2006. ,
DOI : 10.1097/01.wco.0000245368.36576.0d
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society*, European Journal of Neurology, vol.158, issue.10, pp.809-818, 2006. ,
DOI : 10.1182/blood-2004-05-2046
Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies, Acta Neurologica Scandinavica, vol.24, issue.6, pp.383-390, 1992. ,
DOI : 10.1111/j.1600-0404.1992.tb06033.x
Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies, Journal of the Neurological Sciences, vol.114, issue.2, pp.193-199, 1993. ,
DOI : 10.1016/0022-510X(93)90297-C
Peripheral neuropathies associated with monoclonal gammopathies of undetermined significance, Rev Neurol Dis, vol.5, issue.1, pp.14-22, 2008. ,
Malignant transformation in polyneuropathy associated with monoclonal gammopathy, Neurology, vol.64, issue.12, pp.2079-2084, 2005. ,
DOI : 10.1212/01.WNL.0000176296.79088.9A
Comparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients, Journal of Neurology, vol.77, issue.8, pp.1485-1491, 2014. ,
DOI : 10.1007/s00415-014-7357-0
Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy, Annals of Neurology, vol.38, issue.3, pp.416-424, 1994. ,
DOI : 10.1002/ana.410360313
Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, Cochrane Database Syst Rev, issue.4, p.6828, 2008. ,
Effector mechanisms in anti-MAG antibody-mediated and other demyelinating neuropathies, Journal of the Neurological Sciences, vol.220, issue.1-2, pp.127-129, 2004. ,
DOI : 10.1016/j.jns.2004.03.012
Complement-Mediated Demyelination in Patients with IgM Monoclonal Gammopathy and Polyneuropathy, New England Journal of Medicine, vol.322, issue.10, pp.649-652, 1990. ,
DOI : 10.1056/NEJM199003083221002
Myelin-Associated Glycoprotein Is the Antigen for a Monoclonal IgM in Polyneuropathy, Journal of Neurochemistry, vol.12, issue.5, pp.1261-1265, 1982. ,
DOI : 10.1073/pnas.76.9.4350
Myelin-associated glycoprotein (MAG): past, present and beyond, Journal of Neurochemistry, vol.18, issue.0, pp.1431-1448, 2007. ,
DOI : 10.1111/j.1471-4159.1991.tb08260.x
Myelin-associated glycoprotein and its axonal receptors, Journal of Neuroscience Research, vol.102, issue.15, pp.3267-3276, 2009. ,
DOI : 10.1002/jnr.21992
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892843
Immunocytological Studies of L-MAG Expression Regulation during Myelination of Embryonic Brain Cell Cocultures, Developmental Neuroscience, vol.24, issue.6, pp.495-503, 2002. ,
DOI : 10.1159/000069360
Multiple functions of the myelin-associated glycoprotein MAG (siglec-4a) in formation and maintenance of myelin, Glia, vol.18, issue.2, pp.154-165, 2000. ,
DOI : 10.1002/(SICI)1098-1136(20000115)29:2<154::AID-GLIA9>3.0.CO;2-3
Expression and function of myelin-associated proteins and their common receptor NgR on oligodendrocyte progenitor cells, Brain Research, vol.1437, pp.1-15 ,
DOI : 10.1016/j.brainres.2011.12.008
Nogo-A and Myelin-Associated Glycoprotein Differently Regulate Oligodendrocyte Maturation and Myelin Formation, Journal of Neuroscience, vol.28, issue.29, pp.7435-7444, 2008. ,
DOI : 10.1523/JNEUROSCI.0727-08.2008
A Hypothesis About the Relationship of Myelin-Associated Glycoprotein???s Function in Myelinated Axons to its Capacity to Inhibit Neurite Outgrowth, Neurochemical Research, vol.206, issue.1, 2009. ,
DOI : 10.1007/s11064-008-9668-y
The cytoplasmic domain of the large myelin-associated glycoprotein isoform is needed for proper CNS but not peripheral nervous system myelination ,
Anti-MAG antibody-associated polyneuropathies: Improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide, Neurology, vol.45, issue.8, pp.1577-1580, 1995. ,
DOI : 10.1212/WNL.45.8.1577
Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group., Journal of Neurology, Neurosurgery & Psychiatry, vol.59, issue.3, pp.243-247, 1995. ,
DOI : 10.1136/jnnp.59.3.243
Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG, Journal of Neuroimmunology, vol.193, issue.1-2, pp.87-93, 2008. ,
DOI : 10.1016/j.jneuroim.2007.10.025
Peripheral neuropathy associated with IgM monoclonal gammopathy: Correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases, Muscle & Nerve, vol.56, issue.1, pp.55-62, 1998. ,
DOI : 10.1002/(SICI)1097-4598(199801)21:1<55::AID-MUS8>3.0.CO;2-F
Neuropathy associated with ?benign? anti-myelin-associated glycoprotein IgM gammopathy: Clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases, Journal of Neurology, vol.238, issue.Suppl 44, 1996. ,
DOI : 10.1007/BF00878529
CAN ELECTROPHYSIOLOGY DIFFERENTIATE POLYNEUROPATHY WITH ANTI-MAG/SGPG ANTIBODIES FROM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY?, Journal of the Peripheral Nervous System, vol.7, issue.4, pp.346-353, 2002. ,
DOI : 10.1046/j.1529-8027.2002.02032_1.x
Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients., Journal of Neurology, Neurosurgery & Psychiatry, vol.61, issue.1, pp.36-42, 1996. ,
DOI : 10.1136/jnnp.61.1.36
Tremor associated with benign IgM paraproteinaemic neuropathy, Brain, vol.119, issue.3, pp.789-799, 1996. ,
DOI : 10.1093/brain/119.3.789
Physiological tremor analysis of patients with anti-myelin-associated glycoprotein associated neuropathy and tremor. Muscle Nerve, pp.38-44, 1997. ,
The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS, Can J Neurol Sci J Can Sci Neurol, 2011. ,
196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8???10 February 2013, Naarden, The Netherlands, Neuromuscular Disorders, vol.23, issue.11, pp.924-933, 2013. ,
DOI : 10.1016/j.nmd.2013.06.006
Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy, Annals of Neurology, vol.40, issue.2, pp.195-201, 2001. ,
DOI : 10.1002/ana.1088
Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients' own clinical judgement in immune-mediated polyneuropathies, Journal of Neurology, Neurosurgery & Psychiatry, vol.77, issue.8, pp.970-972, 2006. ,
DOI : 10.1136/jnnp.2005.076174
Inflammatory Neuropathy Cause and Treatment (INCAT) group. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies, J Neurol Neurosurg Psychiatry, 2002. ,
A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale, Journal of Neurology, Neurosurgery & Psychiatry, vol.77, issue.8, pp.973-976, 2006. ,
DOI : 10.1136/jnnp.2005.081547
Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies, Neurology, vol.76, issue.4, pp.337-345, 2011. ,
DOI : 10.1212/WNL.0b013e318208824b
Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group, Neurology. Feb, vol.2254, issue.4, pp.943-949, 2000. ,
Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve, 1991. ,
Quality of life complements traditional outcome measures in immune-mediated polyneuropathies, Neurology, vol.59, issue.1, pp.84-91, 2002. ,
DOI : 10.1212/WNL.59.1.84
Reliability of the Modified Rankin Scale: A Systematic Review, Stroke, vol.40, issue.10, pp.3393-3395, 2009. ,
DOI : 10.1161/STROKEAHA.109.557256
Length dependence in polyneuropathy associated with IgM gammopathy, Annals of Neurology, vol.58, issue.2, pp.365-371, 2006. ,
DOI : 10.1002/ana.20785
Distal motor latency and residual latency as sensitive markers of anti-MAG polyneuropathy, Journal of Neurology, vol.250, issue.8, pp.962-966, 2003. ,
DOI : 10.1007/s00415-003-1128-7
Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside, Brain, vol.117, issue.5, pp.941-947, 1994. ,
DOI : 10.1093/brain/117.5.941
Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies, Clinical Neurophysiology, vol.112, issue.3, pp.457-463, 2001. ,
DOI : 10.1016/S1388-2457(01)00469-2
Terminal latency index in polyneuropathy with IgM paraproteinemia and anti-MAG antibody. Muscle Nerve, pp.1278-1282, 2001. ,
Terminal latency index in neuropathy with antibodies against myelin-associated glycoproteins. Muscle Nerve, 2007. ,
Electrophysiologic study of experimental demyelination induced by serum of patients with IgM M proteins and neuropathy, Neurology, vol.39, issue.12, pp.1581-1586, 1989. ,
DOI : 10.1212/WNL.39.12.1581
Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature, Journal of Neurology, vol.260, issue.7, pp.1398-1404 ,
DOI : 10.1007/s00415-014-7354-3
Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy, Neurology, vol.73, issue.9, pp.688-695, 2009. ,
DOI : 10.1212/WNL.0b013e3181b59a80
Diagnostic value of autoantibodies to MAG by ELISA Bühlmann in 117 immune-mediated peripheral neuropathies associated with monoclonal IgM to SGPG, Ann Biol Clin, vol.64, issue.4, pp.353-359, 2006. ,
Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve, pp.637-643, 1996. ,
Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia, Journal of Neuroimmunology, vol.95, issue.1-2, pp.174-184, 1999. ,
DOI : 10.1016/S0165-5728(98)00247-1
Pathogenesis and Treatment of Anti-MAG Neuropathy, Current Treatment Options in Neurology, vol.29, issue.1, pp.71-83, 2010. ,
DOI : 10.1007/s11940-010-0065-x
Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing, Brain, vol.125, issue.4, pp.904-911, 2002. ,
DOI : 10.1093/brain/awf072
URL : http://doi.org/10.1093/brain/awf072
Myelin widenings and MGUS-IgA: An immunoelectron microscopic study, Annals of Neurology, vol.117, issue.6, pp.808-811, 2000. ,
DOI : 10.1002/1531-8249(200006)47:6<808::AID-ANA15>3.0.CO;2-8
Polyneuropathy and IgM monoclonal gammopathy: Studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody, Annals of Neurology, vol.34, issue.3, pp.243-254, 1985. ,
DOI : 10.1002/ana.410170305
Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies, Brain, vol.123, issue.4, pp.710-717, 2000. ,
DOI : 10.1093/brain/123.4.710
Polyneuropathy associated with monoclonal gammopathy of undetermined significance, Brain, vol.117, issue.6, pp.1385-1393, 1994. ,
DOI : 10.1093/brain/117.6.1385
The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia, Brain, vol.117, issue.5, pp.949-957, 1994. ,
DOI : 10.1093/brain/117.5.949
Long-term clinical and neurophysiological follow-up of patients with peripheral, neuropathy associated with benign monoclonal gammopathy, Muscle & Nerve, vol.238, issue.2, pp.164-174, 2000. ,
DOI : 10.1002/(SICI)1097-4598(200002)23:2<164::AID-MUS4>3.0.CO;2-Y
Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenstr??m Macroglobulinemia, Clinical Lymphoma Myeloma and Leukemia, vol.13, issue.2, pp.184-186 ,
DOI : 10.1016/j.clml.2013.02.005
Survival in Monoclonal Gammopathy of Undetermined Significance and Waldenstr??m Macroglobulinemia, Clinical Lymphoma Myeloma and Leukemia, vol.13, issue.2, pp.187-190 ,
DOI : 10.1016/j.clml.2013.02.010
Monoclonal gammopathy of undetermined significance: a consensus statement, British Journal of Haematology, vol.22, issue.Suppl. 2, pp.28-38, 2010. ,
DOI : 10.1111/j.1365-2141.2010.08207.x
Systemic manifestations of monoclonal gammopathy, European Journal of Internal Medicine, vol.20, issue.5, pp.457-461, 2009. ,
DOI : 10.1016/j.ejim.2009.01.001
Diagnosis and Management of Waldenstr??m Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines, Mayo Clinic Proceedings, vol.85, issue.9, pp.824-833, 2010. ,
DOI : 10.4065/mcp.2010.0304
Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies, Cochrane Database Syst Rev, vol.5, p.2827, 2012. ,
Plasma Exchange in Polyneuropathy Associated with Monoclonal Gammopathy of Undetermined Significance, New England Journal of Medicine, vol.325, issue.21, pp.1482-1486, 1991. ,
DOI : 10.1056/NEJM199111213252105
Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve, pp.778-786, 2001. ,
Pulsed high-dose dexamethasone treatment of polyneuropathy associated with monoclonal gammopathy, Journal of Neurology, vol.244, issue.7, pp.462-463, 1997. ,
DOI : 10.1007/s004150050124
A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy, Journal of Neurology, vol.249, issue.10, pp.1370-1377, 2002. ,
DOI : 10.1007/s00415-002-0808-z
A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy, Annals of Neurology, vol.322, issue.5, pp.792-795, 1996. ,
DOI : 10.1002/ana.410400516
A randomised double blind trial versus placebo does not confirm the benefit of alpha -interferon in polyneuropathy associated with monoclonal IgM, Journal of Neurology, Neurosurgery & Psychiatry, vol.69, issue.2 ,
DOI : 10.1136/jnnp.69.2.279
A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM, Journal of Neurology, Neurosurgery & Psychiatry, vol.63, issue.1, pp.28-34, 1997. ,
DOI : 10.1136/jnnp.63.1.28
Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies, Cochrane Database Syst Rev Online, issue.2, p.2827, 2006. ,
Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy, Neurology, vol.69, issue.1, pp.50-59, 2007. ,
DOI : 10.1212/01.wnl.0000265055.28218.cc
Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance, Neurology, vol.47, issue.5, pp.1227-1233, 1996. ,
DOI : 10.1212/WNL.47.5.1227
Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy, Neurology, vol.67, issue.11, pp.2076-2079, 2006. ,
DOI : 10.1212/01.wnl.0000247671.58066.21
Successful treatment of IgM paraproteinaemic neuropathy with fludarabine, Journal of Neurology, Neurosurgery & Psychiatry, vol.66, issue.5, pp.575-580, 1999. ,
DOI : 10.1136/jnnp.66.5.575
Cladribine in the treatment of IgM paraproteinemic polyneuropathy, Neurology, vol.59, issue.8, pp.1290-1291, 2002. ,
DOI : 10.1212/WNL.59.8.1290
Nervous system dysfunction in Waldenstrom's macroglobulinemia: Response to treatment, Neurology, vol.51, issue.4, pp.1210-1213, 1998. ,
DOI : 10.1212/WNL.51.4.1210
Predictors of response to rituximab in patients with neuropathy and anti?myelin associated glycoprotein immunoglobulin M, Journal of the Peripheral Nervous System, vol.322, issue.2, pp.102-107, 2007. ,
DOI : 10.1212/01.wnl.0000201193.00382.b3
Tolerability and safety of rituximab (MabThera??), Cancer Treatment Reviews, vol.31, issue.6, 2005. ,
DOI : 10.1016/j.ctrv.2005.05.007
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis, The Lancet Neurology, vol.9, issue.4, pp.425-437 ,
DOI : 10.1016/S1474-4422(10)70040-5
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880524
Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies, Journal of Neurology, vol.80, issue.9, 2011. ,
DOI : 10.1007/s00415-011-5994-0
URL : https://hal.archives-ouvertes.fr/hal-00703179
Rituximab for polyneuropathy with IgM monoclonal gammopathy, Journal of Neurology, Neurosurgery & Psychiatry, vol.80, issue.9, pp.1036-1039, 2009. ,
DOI : 10.1136/jnnp.2008.155325
Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve, pp.611-615, 2003. ,
High-dose rituximab and anti-MAG-associated polyneuropathy, Neurology, vol.66, issue.5, pp.742-744, 2006. ,
DOI : 10.1212/01.wnl.0000201193.00382.b3
Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy, Annals of Neurology, vol.358, issue.5 pt 1, 2009. ,
DOI : 10.1002/ana.21577
Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy, Neurology, vol.80, issue.24, pp.2217-2225, 2013. ,
DOI : 10.1212/WNL.0b013e318296e92b
Rituximab Improves Subclinical Temporal Dispersion of Distal Compound Muscle Action Potential in Anti-MAG/SGPG Neuropathy Associated with Waldenstr??m Macroglobulinemia: A Case Report, Case Reports in Neurology, vol.5, issue.1, pp.34-39 ,
DOI : 10.1159/000348395
Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab, Haematologica, vol.91, issue.6, p.17, 2006. ,
Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy, Journal of the Neurological Sciences, vol.345, issue.1-2, 2014. ,
DOI : 10.1016/j.jns.2014.07.055
Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment, Journal of the Peripheral Nervous System, vol.61, issue.Suppl. 3, pp.189-191 ,
DOI : 10.1111/jns5.12018
Initial immunoglobulin M ?flare? after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia, Cancer, vol.1, issue.11, pp.2593-2598, 2004. ,
DOI : 10.1002/cncr.20658
Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients, Haematologica, vol.98, issue.12, pp.155-157, 2013. ,
DOI : 10.3324/haematol.2013.087213
Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy, Journal of the Peripheral Nervous System, vol.66, issue.3, pp.180-185, 2011. ,
DOI : 10.1111/j.1529-8027.2011.00343.x
Treatment of IgM antibody associated polyneuropathies using rituximab, Journal of Neurology, Neurosurgery & Psychiatry, vol.74, issue.4, 2003. ,
DOI : 10.1136/jnnp.74.4.485
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Cancer Netw JNCCN, pp.1211-1219, 2012. ,
DOI : 10.6004/jnccn.2012.0128
Fatal peripheral neuropathy with predominant motor involvement associated with anti-MAG IgM monoclonal gammapathy], Rev Neurol, vol.149, pp.8-9496, 1993. ,
IgM MGUS anti-MAG neuropathy with predominant muscle weakness and extensive muscle atrophy. Muscle Nerve, 2010. ,
Neuropathy with Predominant Small Fiber Involvement Associated with Abnormal Anti-MAG Titer, Internal Medicine, vol.49, issue.23, pp.2627-2629, 2010. ,
DOI : 10.2169/internalmedicine.49.4200
Multifocal motor neuropathy with high titers of anti-MAG antibodies, Journal of the Peripheral Nervous System, vol.68, issue.2, pp.10-1111, 2014. ,
DOI : 10.1111/jns5.12069
Delayed apperance of anti-myelin-associated glycoprotein antibodies in a patient with chronic demyelinating polyneuropathy, Annals of Neurology, vol.26, issue.3, pp.394-396, 1993. ,
DOI : 10.1002/ana.410340314
Coexistence of hereditary motor and sensory neuropathy type IA and IGM paraproteinemic neuropathy, Annals of Neurology, vol.339, issue.6, pp.649-652, 1993. ,
DOI : 10.1002/ana.410330615
IgM monoclonal gammopathy and neuropathy in two siblings., Journal of Neurology, Neurosurgery & Psychiatry, vol.51, issue.10, pp.1308-1315, 1988. ,
DOI : 10.1136/jnnp.51.10.1308
Three Families With Polyneuropathy Associated With Monoclonal Gammopathy, Archives of Neurology, vol.57, issue.5, 2000. ,
DOI : 10.1001/archneur.57.5.740
Coexistence of Charcot-Marie-Tooth disease type 1A and anti-MAG neuropathy, Journal of the Peripheral Nervous System, vol.8, issue.Suppl 3, pp.185-188 ,
DOI : 10.1111/jns5.12029
An Autopsy Case of Amyotrophic Lateral Sclerosis with Waldenstr??m Macroglobulinemia and Anti-MAG Gammopathy, Case Reports in Neurology, vol.3, issue.3, pp.294-300, 2011. ,
DOI : 10.1159/000335004
Clinical???neurophysiological correlations in a series of patients with IgM-related neuropathy, Clinical Neurophysiology, vol.124, issue.9, pp.1899-1903, 2013. ,
DOI : 10.1016/j.clinph.2013.02.116
MRI of the brachial plexus in polyneuropathy associated with monoclonal gammopathy. Muscle Nerve, pp.1312-1318, 2001. ,
IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy, Annals of Neurology, vol.164, issue.2, pp.180-187, 2005. ,
DOI : 10.1002/ana.20364
Immunoglobulin M Deposition in Cutaneous Nerves of Anti-Myelin-Associated Glycoprotein Polyneuropathy Patients Correlates With Axonal Degeneration, Journal of Neuropathology and Experimental Neurology, vol.68, issue.2, pp.148-158, 2009. ,
DOI : 10.1097/NEN.0b013e3181958187
Nerve ultrasound findings in neuropathy associated with anti-myelin-associated glycoprotein antibodies, European Journal of Neurology, vol.260, issue.1, 2014. ,
DOI : 10.1111/ene.12554
Neuropathy and IgM M-proteins: Prognostic value of antibodies to MAG, SGPG, and sulfatide, Neurology, vol.56, issue.2, pp.228-233, 2001. ,
DOI : 10.1212/WNL.56.2.228
Prognosis of polyneuropathy due to IgM monoclonal gammopathy: A prospective cohort study, Neurology, vol.74, issue.5, pp.406-412, 2010. ,
DOI : 10.1212/WNL.0b013e3181ccc6b9
Total neuropathy score: Validation and reliability study, Neurology, vol.53, issue.8, pp.1660-1664, 1999. ,
DOI : 10.1212/WNL.53.8.1660
Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve, 2002. ,
Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve, pp.378-379, 2005. ,
Chronic neuropathy with IgM anti-ganglioside antibodies: Lack of long term response to rituximab, Neurology, vol.61, issue.12, pp.1814-1816, 2003. ,
DOI : 10.1212/01.WNL.0000098996.02934.86
B-cell-activating factor in rituximab-treated patients with anti-MAG polyneuropathy, Journal of Neurology, Neurosurgery & Psychiatry, vol.82, issue.11, pp.1291-1294, 2011. ,
DOI : 10.1136/jnnp.2010.222216
Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin???s Lymphoma: Safety and Efficacy of Re-Treatment, Journal of Clinical Oncology, vol.18, issue.17, pp.3135-3143, 2000. ,
DOI : 10.1200/JCO.2000.18.17.3135
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis, Arthritis & Rheumatism, vol.52, issue.2, pp.3896-3908, 2007. ,
DOI : 10.1002/art.23059
Deep brain stimulation of the ventral intermediate thalamic nucleus for severe tremor in anti-MAG neuropathy, Movement Disorders, vol.80, issue.14, pp.2157-2158, 2009. ,
DOI : 10.1002/mds.22604
NEUROSURGICAL TREATMENT OF TREMOR IN ANTI-MYELIN-ASSOCIATED GLYCOPROTEIN NEUROPATHY, Neurology, vol.73, issue.20, pp.1707-1708, 2009. ,
DOI : 10.1212/WNL.0b013e3181c1de66
Treatment with botulinum toxin for anti-MAG neuropathy-related arm tremor, Neurological Sciences, vol.18, issue.2, pp.10-1007, 2014. ,
DOI : 10.1007/s10072-014-1890-6
Novel treatment for immune neuropathies on the horizon, Journal of the Peripheral Nervous System, vol.35, issue.2, pp.75-83, 2011. ,
DOI : 10.1111/j.1529-8027.2011.00334.x
Toll-Like Receptor Signaling Is Critical for Wallerian Degeneration and Functional Recovery after Peripheral Nerve Injury, Journal of Neuroscience, vol.27, issue.46, pp.12565-12576, 2007. ,
DOI : 10.1523/JNEUROSCI.3027-07.2007
Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation, Frontiers in Immunology, vol.123, issue.Pt 2, p.367, 2014. ,
DOI : 10.1182/blood-2013-12-543306
URL : http://doi.org/10.3389/fimmu.2014.00367
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia, pp.1722-1728, 2013. ,
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood, pp.503-510, 2014. ,